If you have any questions for our guest speakers (Greatland Gold, Helium One and Poolbeg Pharma), please submit here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,399.60
Bid: 1,394.40
Ask: 1,395.00
Change: -2.20 (-0.16%)
Spread: 0.60 (0.04%)
Open: 1,405.00
High: 1,405.00
Low: 1,389.80
Yest. Close: 1,401.80
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Pernix to buy U.S. marketing rights to GSK, Pozen migraine drug

Wed, 14th May 2014 13:37

May 14 (Reuters) - Pernix Therapeutics Holdings Inc said it would buy the U.S. marketing rights for a migraine treatment developed by GlaxoSmithKline Plc and Pozen Inc for an upfront payment of $250 million.

Pernix's shares jumped as much as 42.5 percent in early trading on the Nasdaq.

The deal will nearly double Pernix's revenue by allowing it to expand its presence in the neurological market, the company said on Wednesday.

Pozen will get a warrant to purchase 500,000 Pernix shares, or about 1.3 percent of its outstanding stock, at Tuesday's closing price of $4.28.

The drug, Treximet, was approved by the U.S. Food and Drug Administration in April 2008 to treat acute migraine attacks in adults.

Pernix plans to the expand the use of the drug for children and expects to file for regulatory approval by the end of the year.

The company said the agreement is expected to close by Aug. 1 and that it will make royalty payments on net sales of the product. Glaxo was marketing the drug in the United States.

Mount Pleasant, South Carolina-based Pernix's shares were up 40 percent at $6.01. Pozen's shares were slightly lower at $8.68. (Reporting by Natalie Grover in Bangalore; Editing by Savio D'Souza)

More News

UPDATE 2-EU starts real-time review of AstraZeneca COVID-19 antibody cocktail

* Treatment is first COVID preventative shot other than vaccines* Drug, Evusheld, shown to save lives and prevent severe disease* EMA gives no timeline for possible approval (Adds detail)Oct 14 (Reuters) - Europe's drug regulator said on Thursday ...

14 Oct 21 13:31

PRESS: Private equity firms eye Glaxo's consumer unit - Bloomberg

PRESS: Private equity firms eye Glaxo's consumer unit - Bloomberg

12 Oct 21 17:21

LONDON MARKET CLOSE: Stocks fall on weakening global growth outlook

LONDON MARKET CLOSE: Stocks fall on weakening global growth outlook

12 Oct 21 17:09

Curevac says 450 mln eur from EU for first-gen vaccine are not refundable

FRANKFURT, Oct 12 (Reuters) - Curevac said it would not have to pay back the 450 million euros ($520 million) it received from the European Union as part of an advance purchasing agreement of COVID-19 vaccines because the funding was not continge...

12 Oct 21 13:38

UPDATE 1-CureVac to drop COVID-19 vaccine candidate, focus on next-gen shot

* Move comes after human trials showed 47% efficacy of vaccine* Shares sink 14% on news* Co pins hopes on next-gen shot it's developing with GSK* Move means supply deal with EU ends (Adds details)BERLIN, Oct 12 (Reuters) - CureVac will withdraw it...

12 Oct 21 12:54

UPDATE 2-CureVac drops COVID-19 vaccine candidate, turns to next-generation shot

* Trials showed 47% efficacy for original vaccine* Move means vaccine supply deal with EU ends* CureVac shares sink almost 14% on news (Adds details)BERLIN, Oct 12 (Reuters) - CureVac will withdraw its first-generation COVID-19 vaccine candidate an...

12 Oct 21 12:54

UPDATE 3-CureVac drops COVID-19 vaccine, pins hope on next-generation shots

* CureVac says 450 mln eur from EU is non-refundable* Trials showed 47% efficacy for original vaccine* Move means vaccine supply deal with EU ends* CureVac shares sink almost 14% (Adds details on EU deal, research focus)By Zuzanna Szymanska and Lud...

12 Oct 21 12:54

Glaxo's consumer arm drawing interest from private equity - report

(Sharecast News) - GlaxoSmithKline shares topped the FTSE 100 index on Tuesday following a report that the pharmaceuticals giant's consumer unit was drawing interest from private equity firms in what could lead to the biggest buyout of all time.

12 Oct 21 12:29

CureVac to withdraw first-generation COVID-19 vaccine candidate

BERLIN, Oct 12 (Reuters) - CureVac will withdraw its first-generation COVID-19 vaccine candidate and focus on collaborating with GSK to develop second-generation mRNA vaccine technology instead, the Germany-based biotechnology company said on Tue...

12 Oct 21 12:06

RPT-CureVac to withdraw first-generation COVID-19 vaccine candidate

(Repeats to more subscribers)BERLIN, Oct 12 (Reuters) - CureVac will withdraw its first-generation COVID-19 vaccine candidate and focus on collaborating with GSK to develop second-generation mRNA vaccine technology instead, the Germany-based biote...

12 Oct 21 12:06

LIVE MARKETS-Late morning single stock market price action burst

* European shares pare losses* Wall Street futures tick up* China's Evergrande continues to weighOct 12 - Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.rese...

12 Oct 21 12:05

UPDATE 2-GSK says on course to demerge consumer arm after report of buyout interest

(Adds GSK statement)Oct 12 (Reuters) - UK drugmaker GlaxoSmithKline said its plan to separate its consumer healthcare unit next year were on track, after Bloomberg reported potential buyout interest in the business from private equity firms such a...

12 Oct 21 11:38

UPDATE 3-GSK on track with consumer split as buyout report boosts shares

* Firms such as Advent, CVC, KKR interested in GSK unit - BBG* GSK says 'far advanced' with plans to separate consumer arm* Drugmaker says 'firmly' on track for split in mid-2022 (Adds detail throughout)By Pushkala Aripaka and Ludwig BurgerOct 12 ...

12 Oct 21 11:38

GlaxoSmithKline to base Consumer Healthcare arm in Weybridge, Surrey

GlaxoSmithKline to base Consumer Healthcare arm in Weybridge, Surrey

12 Oct 21 08:35

Glaxo unveils plans for £120m consumer healhcare HQ ahead of split

(Sharecast News) - GlaxoSmithKline on Monday unveiled plans for a new £120m base for its consumer healthcare operations as it prepares to split into two listed firms.

11 Oct 21 14:42

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.